Cat Jennings
@bsc_vascular
President, Peripheral Vascular at Boston Scientific, Peripheral Interventions @bsc_pi
Big News! The 544th—and final—patient has been enrolled in #HIPEITHO, a landmark RCT comparing EKOS + anticoagulation vs. anticoagulation alone in intermediate-high risk #PE. Thank you to our investigators, @PERTConsortium & @UnimedizinMainz. Learn more: bit.ly/44VQapx
FDA-approved. Clinically proven. Minimally invasive. #RangerDCB brings next-gen performance to #PAD procedures. Explore the new 200cm monorail platform: bit.ly/46vrMxa #DCB
Introducing #ENROUTE: The first and only transcarotid artery revascularization (#TCAR) system that reverses blood flow during stenting to protect the brain. See why physicians are making the switch: bit.ly/44616RY #OnePowerfulSwitch *Available in US only
Headed to #VAM25 & #SVN25 this week? Check out our BSC events! 🗓️ @for_svn @VascularSVS
🗓️ Join us at #NCVH2025 for a live case featuring an expert operator and panel who will discuss the application of #Ranger200cm to treat complex lesions and evidence-based decision making with #drugeluting therapies. #DCB #DrugCoatedBalloon #PAD
Don’t miss our upcoming webinar: "Simply Complicated or Complicatedly Simple?" Join expert faculty and esteemed moderators for an engaging session on interventions for #DVT, featuring #SmartClaw case discussions. 📅Register now: bit.ly/4jUv3tT
Join us at #VS2025 as we dive into real-world venous cases where anatomy, reflux, and technology shape complexity. Discover how #Varithena can simplify even the most unexpected scenarios. Not all cases are what they seem—let’s explore why. #VenousCare #VenousSymposium
Last weekend, physicians from across the U.S. attended our #AdvancedVascularMasterClass to explore emerging vascular tech, share insights & engage in dynamic breakout sessions and discussions. Big thanks to our expert faculty & attendees for a successful event! #MedEd
Join us for an enlightening discussion as thought leaders spanning diverse medical specialties share the latest clinical data & their perspectives on the future of #PE. @PERTConsortium @drksterling @DKadiandodov @monteleoneMD #MedEd Register now: bit.ly/42Uy0o7
Congratulations! 👏 #ENROUTE @bsc_pi
We are excited to share that Dr. Dixon Santana and Dr. Collin Gandillon have performed the first T-CAR procedure at UMC! 💙 T-CAR (Transcarotid Artery Revascularization) is a minimally invasive surgical procedure that treats carotid artery stenosis.
Join us at #VENOUS2025 to hear expert faculty, @drksterling, @DrJCJimenez, Misaki Kiguchi, MD, and Mikel Sadek, MD discuss #Varithena's versatility, effectiveness & unique patent benefits through clinical case presentations & panel discussion. @VenousForum
❤️ Proudly wearing red today along with many of my colleagues on Boston Scientific's Vascular team to raise awareness for women’s heart health! Heart disease is the No. 1 killer of women, claiming one life every minute. #GoRedBSC #WomensHealth @bsc_pi @bostonsci
Reserve your seat for this semi-annual, 2-day educational event focused on #PAD and #VTE, featuring a multidisciplinary expert faculty panel🗓️ #MedEd Pre-register now: qrco.de/AVMC
Big news! Upon close and regulatory approval, we look forward to providing physicians and their patients access to this emerging, high-growth therapy for treatment of complex cardiovascular diseases.
We’ve agreed to acquire @BoltIVL, developer of an intravascular lithotripsy (IVL) offering to treat coronary and peripheral disease, which will expand our cardiovascular portfolio with a complementary & differentiated calcium modification platform. bit.ly/3DXLmG3 $BSX
Continue following Silk Road Medical’s journey, now as a part of #BostonScientific, by following @bsc_pi and @bsc_vascular. #ForwardTogether #ENROUTE
We’re excited to add TCAR technology to Boston Scientific’s portfolio. CAD is a rapidly growing therapy area affecting nearly half a million new patients annually in the US. As one company, we’re excited to bring this therapy to more patients. *Available only in US currently
In the #REALPE Analysis, the in-hospital mortality rates for #EKOS and FlowTriever were found to be comparable. Learn more about real-world evidence and BSC’s dedication to enhancing care for #pulmonaryembolism: bit.ly/4fNLPIJ #WhyWeEKOS
🗓️Join us next week to discuss The "Usual" Intermediate-High Risk PE Case…And "What Else” - The Usual: Standard PE case - What Else: Case with PFO present - What Else: Case with very short duration, low dose lytic protocol Register Today: qrco.de/ViEWebinar
